Small RNAs can be engineered to target and eliminate expression of disease-causing genes or infectious viruses, resulting in the preclinical and clinical development of RNA interference (RNAi) therapeutics using these small RNAs 1 .
To ensure the success of RNAi therapeutics, small hairpin RNAs (shRNAs) must co-opt sufficient quantities of the endogenous microRNA machinery to elicit efficient gene knockdown without impeding normal cellular function. We previously observed liver toxicity-including hepatocyte turnover, loss of gene repression and lethality 2 -in mice receiving high doses of a recombinant adeno-associated virus (rAAV) vector expressing shRNAs (rAAV-shRNAs); however the mechanism by which toxicity ensues has not been elucidated. Using rAAV-shRNAs we have now determined that hepatotoxicity arises when exogenous shRNAs exceed 12% of the total amount of liver microRNAs. After this threshold was surpassed, shRNAs specifically reduced the initially synthesized 22-nucleotide isoform of microRNA (miR)-122-5p without substantially affecting other microRNAs, resulting in functional de-repression of miR-122 target mRNAs. Delivery of a rAAV-shRNA vector expressing mature miR-122-5p could circumvent toxicity, despite the exogenous shRNA accounting for 70% of microRNAs. Toxicity was also not observed in Mir122-knockout mice regardless of the level or sequence of the shRNA. Our study establishes limits to the microRNA machinery that is available for therapeutic siRNAs and suggests new paradigms for the role of miR-122 in liver homeostasis in mice.
RNAi-mediated cleavage of cognate mRNAs can be induced by delivery of small interfering RNAs (siRNAs) or DNA vectors expressing shRNAs. Actionable mutated genes have been successfully targeted in clinical trials, particularly in tissues in which high rates of delivery can be achieved [3] [4] [5] , such as the liver, in which >95% of hepatocytes can be transduced by rAAV vectors 6 . However, overt overexpression of rAAV-shRNAs has the potential to overwhelm the existing RNAi machinery that is used by both microRNAs and shRNAs in the liver, leading to hepatotoxicity 2, 7 . This is unexpected, considering that the liver is tolerant to perturbations of key microRNA components that result in relatively mild phenotypes, such as mice with a Dicer1 deficiency, which are devoid of microRNAs 8, 9 , or mice with a germline ablation of the predominant liver microRNA, miR-122 (refs. 10, 11) . As a result, the mechanism of shRNA-induced liver toxicity is not clear.
To evaluate the consequence of delivering shRNAs on the pools of existing microRNAs, we performed small RNA sequencing (small RNA-seq) of livers from transgenic hAAT mice-which express the human serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 gene (SERPINA1; also known as AAT; encoding α1-antitrypsin). These transgenic hAAT mice were administered 5 × 10 11 vector genomes of rAAV8 vectors expressing shRNAs of various stem lengths (19 nt, 21 nt and 25 nt) that are dependent on Dicer1 processing (Supplementary Fig. 1a ) and that target AAT. The AAT-specific shRNAs were under the control of the strong RNA polymerase (Pol) III U6 promoter (rAAV-U6-shRNA) or the weak Pol III H1 promoter (rAAV-H1-shRNA) and showed robust initial in vivo knockdown of AAT (Fig. 1a,b and Supplementary Fig. 1b) . Substantial, but nonlethal, toxicity ensued for two rAAV-U6-shRNA constructs, as measured by increased serum alanine transaminase (ALT) levels ( Fig. 1c and Supplementary Fig. 1c ).
Sequence reads from the rAAV-H1-shRNA constructs contributed to a mean of 0.78% of the total microRNA pool, equivalent to the ~15th most-expressed microRNA ( Supplementary Table 1 ). In contrast, sequence reads from U6-sh-hAAT-21nt and U6-sh-hAAT-25nt constituted 29.9% and 21.4% of total reads, respectively-which are more than all of the microRNAs in the liver, except for miR-122, in both the total pool of small RNAs and the pool of small RNAs that are immunoprecipitated with argonaute 2 (Ago2) ( Supplementary Table 1 ). Reads from mice that were delivered rAAV-U6-sh-hAAT-19nt constituted 2.2% of total reads, and these mice did not have elevated ALT levels, probably owing to the poor processing of this shRNA ( Supplementary Fig. 1a) . To identify the level of shRNA expression that can lead to toxicity, we tested additional U6-shRNA constructs, including those expressing hepatitis C virus (HCV)-specific shRNAs and those expressing miR-30 (ref. 12) , and H1-sh-hAAT-21nt at increased doses of 1 × 10 12 and 2.5 × 10 12 vector genomes. We found that the shRNA expression levels needed to reach >12% of total microRNA reads to be toxic (Fig. 1d ). This provides an upper limit RNA interference-induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice Unexpectedly, delivery of U6-shRNAs specifically reduced the 22-nt isoform (22-mer) of miR-122-5p, whereas the relative levels of the 21nt isoform increased, and those of the 23-nt species remained constant ( Fig. 2b) . This is in marked contrast to the combined length distribution of all other microRNAs, including the distribution of miR-122-3p species (20-22 nt) , which remained unchanged regardless of the delivery of the rAAV-shRNA vector ( Fig. 2c and Supplementary Fig. 2c ). The 22-mer/21-mer ratio of miR-122-5p isoforms was reduced in all U6-sh-hAAT samples relative to those from the H1-sh-hAAT samples and controls, both in the Ago2-immunoprecipitated and in the total small RNA fractions ( Fig. 2d-f ), but it was not a common feature of other microRNAs ( Supplementary Fig. 2d,e ). In total, 17 shRNAs targeting six different genes had the same disruption in miR-122 isoform profiles ( Supplementary Fig. 2f,g) . Taken together, this suggests that microRNA isoform changes are of consequence only for miR-122-5p. Thus, the exogenously delivered shRNAs in the liver specifically compete with, displace or inhibit the generation of the miR-122-5p 22-mer species.
The differential effect of shRNAs on the miR-122 isoforms prompted us to evaluate how the different isoforms arise, with the intention of determining whether shRNAs affect miR-122 biogenesis or turnover. Consequently, we expressed the miR-122 precursor, with a nucleotide modification in miR-122-5p that would allow us to distinguish it from endogenous miR-122, in human embryonic kidney (HEK) 293 cells ( Fig. 2a) . Time course analysis for miR-122 expression revealed that the 22-mer initially contributes ~90% of miR-122-5p reads 12 h after transfection; this dropped to ~60% by 72 h for the spare endogenous cellular machinery that is available for safe RNAi activity from exogenous constructs.
Despite the high accumulation of shRNA reads, we detected no microRNAs with overt relative expression differences between mice receiving toxic U6-shRNAs and those receiving nontoxic H1-shR-NAs-including miR-122, which accounts for ~70% of all human and mouse liver microRNAs [13] [14] [15] and for ~65% in mice treated with toxic rAAV-U6-shRNA constructs ( Fig. 1e and Supplementary Tables 2 and 3). However, when we combined reads mapping to microRNAs and shRNAs, we found an ~22% drop in miR-122 expression for toxic U6-shRNAs, which actually exceeds the combined number of reads mapping to the second and third most-expressed microRNAs, miR-21 and let-7a, respectively (Supplementary Table 1 ). The number of miR-122 reads displaced by the exogenous shRNAs was much greater than the total non-miR-122 microRNAs, which remained at ~30% of read counts ( Fig. 1f and Supplementary Fig. 1d,e ). This was not specific to greater expression of one shRNA, because we confirmed these findings using six additional rAAV-U6-shRNA constructs targeting HCV or expressing miR-30. Thus, high shRNA levels selectively displaced miR-122.
Because our small RNA-seq analysis suggested that miR-122 reads are outcompeted by those from shRNAs, we evaluated the small RNAseq reads that mapped to miR-122 to determine whether their composition was altered in any way after delivery of the U6-shRNA vectors. miR-122-5p is present in human and mouse livers in four primary isoforms that are 21-23 nt long ( Fig. 2a and Supplementary Fig. 2a,b) including a 23-nt isoform terminating in a nontemplated adenosine 16 . npg after transfection (Fig. 2g,h and Supplementary Fig. 3a,b ). Further support that the miR-122-5p 22-mer is the first to be synthesized came when we performed a targeted excision of the Mir122 locus in vivo and found that this isomer was predominantly lost ( Fig. 2i) .
Together, these results suggest that the 22-mer isoform of miR-122 is the initial product of Dicer1 cleavage; this is subsequently trimmed or tailed to the 21-or 23-nt species. Therefore our data are consistent with the idea that the loss of the 22-nt isoform we observe in vivo in liver tissues that receive toxic levels of the rAAV-shRNAs represents the loss of newly synthesized miR-122. If miR-122 loss is indeed the primary consequence of high shRNA expression, then we anticipate increased expression of mRNAs bearing miR-122 target matches. To test this, we performed RNA-seq analysis on two groups of livers. One group contained livers from control mice and those that expressed the H1-sh-hAAT-shRNA (H1-shRNA livers) and U6-sh-hAAT-shRNA (U6-shRNA livers) constructs ( Supplementary Fig. 4a and Supplementary Table 4 ). The other group was composed of mouse livers receiving one of five additional U6-shRNAs that target HCV or express miR-30a ( Supplementary Fig. 4b and Supplementary Table 5 ). The overlap of differentially expressed transcripts in both RNA-seq experiments was considerable (P < 1 × 10 −173 by hypergeometric distribution; Fig. 3a ). Gene Ontology (GO) database terms for processes such as oxidative phosphorylation, steroid metabolism and cholesterol biosynthesis were enriched for genes that were significantly (P < 0.05) decreased in U6-shRNA livers. Conversely, genes that were significantly (P < 0.05) upregulated are involved in the innate immune response, viral response and programmed cell death pathways (Fig. 3b,c and Supplementary Fig. 4c,d) .
Several lines of evidence from our RNA-seq analysis indicated specific de-repression of miR-122 targets. First, genes with 3′ untranslated regions (UTRs) that harbor predicted miR-122 targets showed higher expression in U6-shRNA livers ( Fig. 3d,e) , in contrast to the expression for predicted gene targets of miR-21 or let-7. Second, 73 validated targets of miR-122 (ref. 11) were also significantly upregulated in U6-shRNA livers (Supplementary Fig. 4e ). Finally, only the 7-mer seed sequence of miR-122 was enriched, as compared to all of the microRNA seed sequences (Fig. 3f) . Thus, high U6-shRNA expression seems to primarily affect hepatic miR-122 gene targets.
We examined liver pathology after delivery of the shRNAs that induce toxicity; this revealed features reminiscent of hereditary fructose intolerance caused by mutations in aldolase B (ALDOB) 17 . We found that decreased Aldob levels significantly (P = 0.003) correlated with the degree of toxicity in mice, and-similarly to that for individuals with ALDOB mutations-the phenotype was exacerbated by a fructose-rich diet ( Supplementary Fig. 5 and Supplementary  Table 6 ). We also found de-repression of Aldoa, a common feature of miR-122 inhibition 10, 11, [18] [19] [20] [21] [22] [23] . Of note, Aldoa often has opposing expression patterns with miR-122 and Aldob in the developing and mature liver 14, 24, 25 . These findings indicate that in situations in which Aldob is also suppressed-such as in conjunction with rAAV-shRNA delivery-functional metabolic consequences in the liver can occur. We reasoned that if toxicity was related to competition with miR-122, then delivery of a U6-shRNA construct expressing mature miR-122-5p should be tolerated in mice. Mice that received this U6-shRNA-miR-122 construct, which incorporates a marked internal nucleotide (Fig. 2a) , maintained normal ALT levels, in contrast to mice that received a U6-shRNA-miR-30 construct (Fig. 4a,b) . We detected a displacement of 23.4% of reads mapping to the total microRNA pool for the U6-shRNA-miR-122 recipients 1 week after rAAV administration, which was much higher than the minimum proportion (12%) of reads that correlated with toxicity ( Fig. 4c) . miR-122 isoform ratios were also unchanged ( Fig. 4d) . Notably, the levels of the exogenous miR-122 rose to 72% of reads by 8 weeks, almost completely replacing those of the endogenous miR-122 ( Supplementary Fig. 6a ), all while maintaining normal levels of miR-122 mRNA targets, including Aldoa and Slc7a1 (ref. 26) (Fig. 4e) . This indicates that miR-122 is specifically displaced by any delivered non-miR-122 U6-shRNA construct, resulting in toxicity; however, because exogenous U6-shRNA-miR-122 functionally replaces endogenous miR-122, toxicity is abrogated.
On the basis of our studies, we tested the prediction that toxicity would not be induced by rAAV-shRNAs in the Mir122-knockout mouse 10 , as no copies of miR-122 would be available to be outcompeted. Indeed, we found that Mir122 −/− mice that received rAAV-U6-shRNA vectors shown to be toxic in normal mice had normal ALT levels (Fig. 4f) . This occurred despite the robust accumulation of small RNAs, which accounted for 22% of the total microRNA pool for U6-sh-hAAT-25nt constructs and ~50% for U6-sh-HCV-21nt constructs ( Fig. 4g and Supplementary Fig. 6b-e ). Mir122 +/mice showed slightly increased toxicity after rAAV-U6-shRNA delivery, but they nonetheless had a similar reduction in the 22-nt/21-nt isoform ratios of miR-122-5p and loss of shRNA expression 1 month after transduction (Supplementary Fig. 6d,f) . Aldoa and Slc7a1 levels are already high in Mir122 −/− mice, and no further changes were observed after delivery of the U6-shRNA constructs (Fig. 4e) . Mir122 −/− mice are generally more fragile than their wild-type counterparts to several physiological perturbations, making it particularly notable that that they tolerate rAAV-U6-shRNAs more readily than control mice.
Taken together, our data provide strong evidence that shRNA-induced toxicity is solely related to competition with, and a reduction in, the initially produced mature isoform of miR-122 ( Supplementary Fig. 7) . This might explain why a small reduction in the entire miR-122 pool is sufficient for de-repression of target mRNAs. This result is also consistent with the effects of HCV infection, in which, despite a 10 3 -to 10 5 -fold excess of miR-122 as compared to HCV RNA 18, 27 , miR-122 targets are efficiently de-repressed 18 . Blocking miR-122 expression has been pursued for therapeutic purposes 19, 20, 22, 23, 28 . However, competition of the 22-mer by shRNAs is different than that observed through antisense inhibition approaches to miR-122 that differentially target the various isoforms 23 (Supplementary Fig. 8a) . It is possible that newly synthesized miR-122 products have a unique function or that miR-122 needs to be continually synthesized to sequester targets in a timely manner 21 . Notably, the seed sequence of miR-122-5p is unchanged regardless of the length of the isoform that is generated; however, in certain situations regions other than the seed are important for target repression [29] [30] [31] .
Despite the overwhelming abundance of miR-122 in the liver, Mir122-knockout mice are viable but, over a long period of time, develop liver pathology, including hepatosteatosis, hepatitis and, ultimately, hepatocellular carcinoma 10, 11 . Perhaps the lack of severe npg acute toxicity in mice with a congenital absence of Mir122 is a consequence of their livers not having developed a fully differentiated hepatocyte expression pattern and retaining expression of genes typically restricted to development (Supplementary Fig. 8b) .
Complications and toxicity arising from high doses of shRNA delivery need to be recognized and avoided to ensure safe and sustained gene knockdown, particularly in situations in which rAAV-shRNA constructs are being considered for use in clinical trials 1 . The similarities between human, non-human primate and mouse miR-122 concentrations and isoforms in healthy and disease states, as well as the change in liver gene regulation after the infusion of anti-miR-122 oligonucleotides 20, 22, 28 , point to the potential translation of these findings to human studies. Here we provide important guidelines for in vivo shRNA expression and suggest that RNAi-induced silencing complexes have limits to which they are safely accessible to piggyback therapeutic siRNAs. Moreover, our work provides new insights into the functional role of miR-122, the interplay between miR-122 and exogenously expressed shRNAs in the liver, and the level to which cellular miRNA levels may be altered by shRNAs without affecting metabolic homeostasis in the liver.
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Mouse breeding and recombinant adeno-associated virus (rAAV) transduction.
The Stanford Institute of Medicine Animal Care and Use Committee approved all protocols. The AAV8 serotype was used for all in vivo samples. To test for shRNA efficacy, we generated rAAVs bearing shRNAs against the human alpha-1-antitrypsin (AAT) gene (SERPINA1). 5 × 10 11 vector genomes (in a final volume of 200 µl of PBS) of these shRNAs were injected via the tail vein in mice transgenic for human AAT that have been described previously 32 . For small-RNA-sequencing samples, we used 6-to 8-week-old female C57BL/6 mice, purchased from Jackson Laboratory (Bar Harbor, ME). Three mice in each condition received 5 × 10 11 vector genome shRNAs that were designed to generate an AAT-specific small RNA product of 19 nt, 21 nt or 25 nt stem length driven either by the high-expressing U6 promoter or the low-expressing H1 promoter. Group sizes for animal studies were selected based on numbers historically suitable for detecting effects in ALT levels. Animals were randomly selected to receive various rAAV vectors with respect to control littermates. No animals were excluded from analysis. Additional shRNAs that target HCV, mimic miR-30 or mimic miR-122-5p were delivered under the same parameters. For shRNAs targeting HCV, three stem lengths were used, 21 nt, 29 nt or 29 nt with an internal bulge (29-B) . Those expressing miR-30 contained stem lengths of 21 nt, 24 nt or 24 nt with an internal bulge (24-B). Mir122-knockout mice have been described previously 10 . Female 7-to 9-week-old Mir122 −/− mice were used for infections. The Stanford Department of Comparative Medicine Diagnostic Lab generated metabolic panel values ( Supplementary Table 6 ).
Mir122-knockout mice and Mir122 'floxed' mice, with loxP sites surrounding Mir122, have been described previously 10 . To remove the miR-122 precursor, a rAAV8 vector was generated that expresses Cre under the Eif1a promoter (Addgene plasmid #55636) and was delivered at 1 × 10 12 vector copies per mouse by tail vein injection. Mice heterozygous for Mir122 were generated by breeding Mir122-knockout male mice with C57BL/6 female mice. Table 7 ) have been previously reported 2, 12 . Primers were chemically synthesized (Integrated DNA Technologies), treated with T4 polynucleotide kinase (PNK) and annealed. shRNA constructs bearing Mir122-or AAT-specific sequences were ligated into a BbsI restriction site downstream of a U6 or H1 promoter in a self-complementary rAAV construct. shRNAs expressing a miR-30 sequence or anti-HCV sequence were first ligated into a pBluescript II KS(+) plasmid (Stratagene) containing a U6 promoter using an introduced BglII site and an existing KpnI restriction site. This fragment was then subcloned into a self-complementary rAAV construct using restriction sites NdeI and SalI. rAAVs were generated by triple transfection of pAd5, pAAV8 and various rAAV-shRNA constructs, as described previously 2 .
Plasmid design for expressing shRNAs and miR-122. Primers for generating various shRNAs (Supplementary
The Mir122 sequence, along with ~500 bp of surrounding mouse genomic sequence, was PCR amplified using the primers 5′-AATTGTTGCAAA CAGAGTTCCTG-3′ and 5′−TGCAATCTTTTTATTGACTTGGGAA-3′ with additional NotI and SalI restriction enzymes that enabled cloning into a CMV-expressing construct.
Small RNA deep sequencing. Small RNAs were purified from mouse liver samples snap-frozen and ground into powder in liquid nitrogen using the miRvana kit (Ambion). 1 µg of small RNAs were ligated using T4 RNA ligase in a buffer lacking ATP with 3′ linker-1 (Integrated DNA Technologies) and run on a 15% polyacrylamide gel. A 17-to 28-nt fragment was excised. Samples were 5′ barcoded (4 nt) for multiplex 36-bp sequencing performed on an Illumina GAII machine at the Stanford Functional Genomics Facility (SFGF). Barcodes and linkers were trimmed using custom Perl scripts and then aligned to mouse microRNAs from miRBase (release 15) 33 using Bowtie version 0.12.7 (ref. 34 ) allowing for two mismatches. 5 µg of Trizol-extracted RNA was used for additional shRNAs to confirm findings. These were sequenced using the same protocol on a MiSeq machine (Illumina) at the SFGF. The Deseq R package 35 was used to evaluate microRNA expression between samples. A Benjamini-Hochberg-adjusted P < 0.05 was considered to be significant. To detect microRNA isoform ratios (Fig. 2d) , a minimum mean 20 reads per million mapped microRNA hits was required for both 22-nt and 21-nt isoforms, leaving 66 microRNAs.
For Ago2-immunoprecipitated fractions, a Wako antibody (catalog #015-22031) was used against Ago2. Liver powder samples were incubated with anti-Ago2 overnight at 4 °C, washed three times with cold immunoprecipitation (IP) buffer (20 mM Tris-HCl pH 8.0, 50 mM KCl, 0.2 mM EDTA and 10% glycerol) and eluted in 1 ml of Trizol.
Small RNA deep sequencing data of miR-122-5p isoforms from human liver samples was obtained from GEO submission GSE57381 (ref. 36 ) and data from 'tough decoys' against miR-122 was obtained from GEO record GSE25971 (ref. 23) .
RNA sequencing and analysis. RNA samples were extracted using Trizol (Invitrogen) from mouse liver samples, snap-frozen and ground into powder in liquid nitrogen. RNAs were subjected to poly(A) purification before sequencing using a poly(A) spin kit (New England BioLabs). In total, six samples were prepared using a TruSeq kit (Illumina), barcoded and pooled. Sequencing was performed on an Illumina HiSeq 2500 machine at the Stanford Center for Genomics and Personalized Medicine, generating one lane of paired-end 101-bp reads. We obtained a moderate depth of sequencing (~15 million 100-bp pairedend reads per sample). Reads were aligned to the mouse mm9 genome using TopHat (v.2.0.14) 37,38 to generate BAM files. Sequences were aligned to mouse mRNAs to generate 'fragments per kb of transcript per million mapped reads' (FPKM) values using Cufflinks v.2.2.1 (refs. 37,38) with the following parameters: '-library-norm-method quartile' and removing ribosomal, snoRNA and mitochondrial sequences. Differentially expressed transcripts (Jensen-Shannon divergence false-discovery rate (FDR) < 0.05) were obtained via Cuffdiff as part of the Cufflinks package. Replicate RNA-seq libraries were generated using the same protocol described above, except for the use of the ScriptSeq v2 strand-specific RNA extraction kit (Epicenter) and the option '-library-type fr-secondstrand' in cufflinks transcript mapping. Differentially expressed transcripts (P < 0.05) were obtained via Cuffdiff as part of the Cufflinks package. The overlap of differentially expressed genes between the two sets of samples was evaluated by the DAVID v6.7 Gene Ontology program using a Benjamini P value of <0.05 for significance 39, 40 . Transcripts significantly differentially expressed (by Cuffdiff analysis) between all control + H1 liver samples relative to all rAAV-U6-shRNAs (FDR < 0.001) were analyzed by the Ingenuity Pathway Analysis program using default settings. Seed matches of genes ranked in order (U6/(H1 + control) were evaluated for significantly enriched 7-nt seed sequences by the Sylamer algorithm 41 . Cluster analysis was performed with the DeSeq R package 35 . miR-122 and miR-21 3′ UTR targets were obtained from DIANA microT-CDS v5 (ref. 42) . Sequence data has been deposited in the NCBI GEO repository with the accession number GSE69186.
Alanine transaminase (ALT) and human a1-antitrypsin (AAT) measurements. Mouse serum was collected by centrifugation of blood that was obtained by retro-orbital bleeding. Alanine aminotransferase (ALT) levels were calculated using an ALT kinetic measurement kit (Teco Diagnostics). hAAT levels were determined by enzyme-linked immunosorbent assay (ELISA) as described previously 43 . The investigators were blinded to samples for hAAT and ALT measurements.
Cell culture. Human embryonic kidney (HEK) 293 cells were grown in Dulbecco's modified Eagle's medium (Gibco-BRL) supplemented with nonessential amino acids, penicillin-streptomycin, sodium pyruvate, l-glutamine and 10% heat-inactivated FBS. HEK293 cells were obtained from ATCC, were routinely tested for mycoplasma contamination and were used solely as a vehicle for determining small RNA read counts from transfected plasmids. Cells were transfected with 1 µg of CMV-miR-122 in 12-well plates using Lipofectamine 2000, and RNA was extracted by Trizol at various time points after transfection. Dicer1-knockout cell lines were obtained from the Cullen laboratory 44 , transfected with various H1-shAAT and U6-shAAT plasmids in 12-well plates and extracted 24 h after transfection.
Quantitative RT-PCR. Probes for Aldoa (Mm00833172_g1), Aldob (Mm00523293_m1), Slc7a1 (Mm01219060_m1), delta-like 1 homolog (Dlk1) (Mm00494477_m1), maternally expressed 3 (Meg3) (Mm00522599_m1), npg
